Seed sequence-matched controls reveal limitations of small interfering RNA knockdown in functional and structural studies of hepatitis C virus NS5A-MOBKL1B interaction

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11022-11033

  Chung, Hyo Young ^a   Gu, Meigang ^a   Buehler, Eugen ^b   MacDonald, Margaret R ^a   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; MOBKL1B PROTEIN; NONSTRUCTURAL PROTEIN 5A; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; MOB1A PROTEIN, HUMAN; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL VIABILITY; CONTROLLED STUDY; GENE SILENCING; HEPATITIS C VIRUS; HYDROGEN BOND; NONHUMAN; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; RNA REPLICATION; VIRUS ENTRY; VIRUS REPLICATION; AMINO ACID SEQUENCE; ARTIFACT; CYTOLOGY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; LIVER CELL; METABOLISM; MOLECULAR DOCKING; MOLECULAR GENETICS; PROTEIN ANALYSIS; TUMOR CELL LINE; VIROLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ARTIFACTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; RNA, SMALL INTERFERING; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84906971908     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01582-14     Document Type: Article

References (48)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:296- 305. http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00008.
2. Schinazi R, Halfon P, Marcellin P, Asselah T. 2014. HCV direct-actingantiviral agents: the best interferon-free combination. Liver Int. 34:69-78. http://dx.doi.org/10.1111/liv.12423.
3. Tellinghuisen TL, Rice CM. 2002. Interaction between hepatitis C virus proteins and host cell factors. Curr. Opin. Microbiol. 5:419-427. http: //dx.doi.org/10.1016/S1369-5274(02)00341-7.
4. Pawlotsky JM. 2013. NS5A inhibitors in the treatment of hepatitis C. J. Hepatol. 59:375-382. http://dx.doi.org/10.1016/j.jhep.2013.03.030.
5. Blight KJ, Kolykhalov AA, Rice CM. 2000 Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org/10.1126/science.290.5498.1972.
6. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S, Engel U, Bartenschlager R. 2008 Essential role of domain 3 of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog. 4:e1000035. http://dx.doi.org/10.1371/journal.ppat.1000035.
7. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM. 2008. Identification of residues required for RNA replication in domain 2 and 3 of the hepatitis C virus NS5A protein. J. Virol. 82:1073-1083. http://dx.doi.org/10.1128/JVI.00328-07.
8. Zhao B, Tumaneng K, Guan KL. 2011. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 13: 877-883. http://dx.doi.org/10.1038/ncb2303.
9. Zeng Q, Hong W. 2008. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 13:188-192. http://dx.doi.org/10.1016/j.ccr.2008.02.011.
10. Harvey K, Tapon N. 2007. The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network. Nat. Rev. Cancer 7:182-191. http://dx.doi.org/10.1038/nrc2070.
11. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lohmann V, Luban J, Bartenschlager R. 2009 Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 5:e1000546. http://dx.doi.org/10.1371/journal.ppat.1000546.
12. Hanoulle X, Badillo A, Wieruszeski JM, Verdegem D, Landrieu I, Bartenschlager R, Penin F, Lippens G. 2009. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J. Biol. Chem. 284:13589-13601. http://dx.doi.org/10.1074/jbc.M809244200.
13. Yang F, Robotham JM, Grise H, Frausto S, Madan V, Zayas M, Bartenschlager R, Robinson M, Greenstein AE, Nag A, Logan TM, Bienkiewicz E, Tang H. 2010 A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog. 6:e1001118. http://dx.doi.org/10.1371/journal.ppat.1001118.
14. Foster TL, Gallay P, Stonehouse NJ, Harris M. 2011. Cyclophilin A interacts with domain 2 of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. Virol. 85:7460-7464. http://dx.doi.org/10.1128/JVI.00393-11.
15. Baugh JM, Garcia-Rivera JA, Gallay PA. 2013. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res. 100: 555-561.http://dx.doi.org/10.1016/j.antiviral.2013.09.020.
16. Lindenbach BD, Evans MJ, Syder AJ, Wo¨lk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
17. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413. http://dx.doi.org/10.1073/pnas.0504877103.
18. Schaller T, Appel N, Koutsoudakis G, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. 2007. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J. Virol. 81:4591-4603. http://dx.doi.org/10.1128/JVI.02144-06.
19. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED, Rice CM, Dustin LB. 2008. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48:1843-1850. http://dx.doi.org/10.1002/hep.22550.
20. Scheel TKH, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. RecombinantHCVvariants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 140:1032-1043. http://dx.doi.org/10.1053/j.gastro.2010.11.036.
21. Langelier C, von Schwedler UK, Fisher RD, De Domenico I, White PL, Hill CP, Kaplan J, Ward D, Sundquist WI. 2006. Human ESCRT-II complex and its role in human immunodeficiency virus type 1 release. J. Virol. 80:9465-9480. http://dx.doi.org/10.1128/JVI.01049-06.
22. Mossessova E, Lima CD. 2000. Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol. Cell 5:865-876. http://dx.doi.org/10.1016 /S1097-2765(00)80326-3.
23. Johnsson B, Lofas S, Lindquist G. 1991. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198:268-277. http://dx.doi.org/10.1016/0003-2697(91)90424-R.
24. Myszka DG. 1999. Improving biosensor analysis. J. Mol. Recognit. 12: 279-284. 10556875 Year does not match (PubMed did not provide). http://dx.doi.org/10.1002/(SICI)1099-1352(199909/10)12:5279::AID-JMR4733.0.CO;2-3.
25. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol. 276:307-326. http://dx.doi.org/10.1016/S0076-6879(97)76066-X.
26. CCP4. 1994 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50:760-763. http://dx.doi.org/10.1107/S0907444994003112.
27. Stavridi ES, Harris KG, Huyen Y, Bothos J, Verwoerd PM, Stayrook SE, Pavletich NP, Jeffrey PD, Luca FC. 2003. Crystal structure of a human Mob1 protein: toward understanding Mob-regulated cell cycle pathways. Structure 11:1163-1170. http://dx.doi.org/10.1016/S0969-2126(03)00182-5.
28. Bru¨nger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54:905-921. http://dx.doi.org/10.1107/S0907444998003254.
29. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. 1991 Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47:110-119. http://dx.doi.org/10.1107/S0108767390010224.
30. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT. 2009. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5:298-307. http://dx.doi.org/10 .1016/j.chom.2009.02.001.
31. Witteveldt J, Evans MJ, Bitzegelo J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH. 2009. CD81 is dispensable for hepatitis C virus cell-to cell transmission in hepatoma cells. J. Gen. Virol. 90:48-58. http://dx.doi.org/10.1099/vir.0.006700-0.
32. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wo¨lk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. http://dx.doi.org/10.1038/nature05654.
33. Buehler E, Chen Y, Martin S. 2012. C911: A bench-level control for sequence specific siRNA off-target effects. PLoS One 7:e51942. http://dx.doi.org/10.1371/journal.pone.0051942.
34. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A. 2006. 3= UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3:199-204. http://dx.doi.org/10.1038/nmeth854.
35. Andrus L, Marukina S, Jones CT, Catanese MT, Sheahan TP, Schoggins JW, Barry WT, Dustin LB, Trehan K, Ploss A, Bhatia SN, Rice CM. 2011. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 54:1901-1912. http://dx.doi.org/10.1002/hep.24557.
36. Nishio M, Hamada K, Kawahara K, Sasaki M, Noguchi F, Chiba S, Mizuno K, Suzuki SO, Dong Y, Tokuda M, Morikawa T, Hikasa H, Eggenschwiler J, Yabuta N, Nojima H, Nakagawa K, Hata Y, Nishina H, Mimori K, Mori M, Sasaki T, Mak TW, Nakano t, Itami S, Suzuki A. 2012. Cancer susceptibility and embryonic lethality in Mob1a/1b doublemutant mice. J. Clin. Invest. 122:4505-4518. http://dx.doi.org/10.1172/JCI63735.
37. Mohr S, Bakal C, Perrimon N. 2010. Genomic screening with RNAi: results and challenges. Annu. Rev. Biochem. 79:37-64. http://dx.doi.org/10.1146/annurev-biochem-060408-092949.
38. Arbuthnot P, Carmona S, Ely A. 2005. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver Int. 25:9-15. http://dx.doi.org/10.1111/j.1478-3231.2004.0966.x.
39. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. 2004. TheNS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem. 279:48576-48587. http://dx.doi.org/10.1074/jbc.M407787200.
40. Brass V, Bieck E, Montserret R, Wo¨lk B, Hellings JA, Blum HE, Penin F, Moradpour D. 2002. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 277:8130-8139. http://dx.doi.org/10.1074/jbc.M111289200.
41. Liang Y, Ye H, Kang CB, Yoon HS. 2007. Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. Biochemistry 46:11550-11558. http://dx.doi.org/10.1021/bi700776e.
42. Tan SL, Nakao H, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG. 1999. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc. Natl. Acad. Sci. U. S. A. 96:5533-5538. http://dx.doi.org/10.1073/pnas.96.10.5533.
43. Pflugheber J, Fredericksen B, Sumpter R, Jr., Wang C, Ware F, Sodora DL, Gale M, Jr. 2002 Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc. Natl. Acad. Sci. U. S. A. 99:4650-4655. http://dx.doi.org/10.1073/pnas.062055699.
44. Shirota Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, Murakami S. 2002. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J. Biol. Chem. 277:11149-11155. http://dx.doi.org/10.1074/jbc.M111392200.
45. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, Johnson RL. 2010 Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. U. S. A. 107:1437-1442. http://dx.doi.org/10.1073/pnas.0911427107.
46. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, Wang CY, Gao B, Jiang J, Yang Y. 2010. Mammalian MstI and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc. Natl. Acad. Sci. U. S. A. 107:1431-1436. http://dx.doi.org/10.1073/pnas.0911409107.
47. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasier W, Lee JT, Avruch J, Bardeesy N. 2009. MstI and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16:425-438. http: //dx.doi.org/10.1016/j.ccr.2009.09.026.
48. Hirabayashi S, Nakagawa K, Sumita K, Hidaka S, Kawai T, Ikeda M, Kawata A, Ohno K, Hata Y. 2008. Threonine 74 of MOB1 is a putative key phosphorylation site by MST2 to form the scaffold to activate nuclear Dbf2-related kinase 1. Oncogene 21:4281-4292. http://dx.doi.org/10.1038/onc.2008.66.